Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Drug Investigation
Published in: Clinical Drug Investigation 10/2015

01-10-2015 | Original Research Article

Effect of Rebamipide on the Premalignant Progression of Chronic Gastritis: A Randomized Controlled Study

Authors: Xue Han, Kui Jiang, Bangmao Wang, Lu Zhou, Xin Chen, Shu Li

Published in: Clinical Drug Investigation | Issue 10/2015

Login to get access

Abstract

Background and Objective

Chronic gastritis frequently progresses into precancerous intestinal metaplasia and intraepithelial neoplasia lesions. Rebamipide is a free radical scavenger and we assessed its efficacy on clinical symptoms, gastric mucosal lesions, pathologic grade, and immunohistochemistry in chronic gastritis patients.

Methods

178 eligible patients were randomized into treatment and control groups. Both groups followed an optimized lifestyle for 26 weeks, but the treatment group was additionally medicated with rebamipide 0.1 g three times per day. Upper gastrointestinal endoscopy was performed in all patients to evaluate the severity of gastritis by the Modified Lanza Scoring (MLS) and histological changes were evaluated by the Updated Sydney System Score (USSS). Gastric mucosa immunohistochemistry in the treatment group was performed using the intestinal metaplasia markers caudal type homeobox transcription factor 2 (CDX2) and trefoil factor 3 (TFF3) detection.

Results

There were significant outcome differences between the treatment and control groups regarding the clinical symptom scores (2.62 ± 1.86 vs. 1.55 ± 1.61, P = 0.0001), gastric mucosal lesion scores (0.57 ± 1.05 vs. 0.16 ± 0.90, P = 0.002), and inflammation (P < 0.05). Only in the treated patients were the rates of intestinal metaplasia (P = 0.017 vs. P = 0.123) and low-grade intraepithelial neoplasia (P = 0.005 vs. P = 0.226) significantly reduced after 26 weeks. The percentages of CDX2 (31.5 vs. 15.7 %, P = 0.021) and TFF3 (44.9 vs. 25.8 %, P = 0.012) expressing gastric mucosa cells were significantly lower after rebamipide medication than pre-treatment values.

Conclusions

Rebamipide improved the clinical symptoms, gastric mucosal lesions, and pathological grades of chronic gastritis patients and decreased the expression rates of CDX2 and TFF3 in gastric cells.
Literature
1.
Chang CS, Chen WN, Lin HH, Wu CC, Wang CJ. Increased oxidative DNA damage, inducible nitric oxide synthase, nuclear factor kappaB expression and enhanced antiapoptosis-related proteins in Helicobacter pylori-infected non-cardiac gastric adenocarcinoma. World J Gastroenterol. 2004;10:2232–40.CrossRefPubMed
2.
Farinati F, Cardin R, Degan P, Rugge M, Mario FD, Bonvicini P, et al. Oxidative DNA damage accumulation in gastric carcinogenesis. Gut. 1998;42:351–6.PubMedCentralCrossRefPubMed
3.
Ito M, Haruma K, Kamada T, Mihara M, Kim S, Kitadai Y, et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther. 2002;16:1449–56.CrossRefPubMed
4.
Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772–81.PubMedCentralCrossRefPubMed
5.
Rugge M, Capelle LG, Cappellesso R, Nitti D, Kuipers EJ. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol. 2013;27:205–23.CrossRefPubMed
6.
Yakirevich E, Resnick MB. Pathology of gastric cancer and its precursor lesions. Gastroenterol Clin N Am. 2013;42:261–84.CrossRef
7.
Almeida R, Silva E, Santos-Silva F, Silberg DG, Wang J, De Bolos C, et al. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol. 2003;199:36–40.CrossRefPubMed
8.
Bai YQ, Yamamoto H, Akiyama Y, Tanaka H, Takizawa T, Koike M, et al. Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Lett. 2002;176:47–55.CrossRefPubMed
9.
Bornschein J, Wex T, Peitz U, Kuester D, Roessner A, Malfertheiner P. The combined presence of H. pylori infection and gastro-oesophageal reflux disease leads to an up-regulation of CDX2 gene expression in antrum and cardia. J Clin Pathol. 2009;62:254–9.CrossRefPubMed
10.
Xiao ZY, Ru Y, Sun JT, Gao SG, Wang YF, Wang LD, et al. Expression of CDX2 and villin in gastric cardiac intestinal metaplasia and the relation with gastric cardiac carcinogenesis. Asian Pac J Cancer Prev. 2012;13:247–50.CrossRefPubMed
11.
Shiotani A, Iishi H, Uedo N, Ishihara R, Ishiguro S, Tatsuta M, et al. Helicobacter pylori-induced atrophic gastritis progressing to gastric cancer exhibits sonic hedgehog loss and aberrant CDX2 expression. Aliment Pharmacol Ther. 2006;24(Suppl 4):71–80.CrossRefPubMed
12.
Mutoh H, Sakurai S, Satoh K, Tamada K, Kita H, Osawa H, et al. Development of gastric carcinoma from intestinal metaplasia in Cdx2-transgenic mice. Cancer Res. 2004;64:7740–7.CrossRefPubMed
13.
Huang Z, Zhang X, Lu H, Wu L, Wang D, Zhang Q, et al. Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: a monocentric cohort study in China. BMC Gastroenterol. 2014;14:74.PubMedCentralCrossRefPubMed
14.
Aikou S, Ohmoto Y, Gunji T, Matsuhashi N, Ohtsu H, Miura H, et al. Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening. Gastroenterology. 2011;141(837–45):e1–7.PubMed
15.
Kim JS, Kim JM, Jung HC, Song IS. Expression of cyclooxygenase-2 in human neutrophils activated by Helicobacter pylori water-soluble proteins: possible involvement of NF-kappaB and MAP kinase signaling pathway. Dig Dis Sci. 2001;46:2277–84.CrossRefPubMed
16.
Sakurai K, Sasabe H, Koga T, Konishi T. Mechanism of hydroxyl radical scavenging by rebamipide: identification of mono-hydroxylated rebamipide as a major reaction product. Free Radic Res. 2004;38:487–94.CrossRefPubMed
17.
Iijima K, Ichikawa T, Okada S, Ogawa M, Koike T, Ohara S, et al. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig Dis Sci. 2009;54:1500–7.PubMedCentralCrossRefPubMed
18.
Qi Z, Jie L, Haixia C, Xiaoying Z. Effect of rebamipide on quality of peptic ulcer healing in rat. Dig Dis Sci. 2009;54:1876–83.CrossRefPubMed
19.
20.
Di Rienzo TA, D’Angelo G, Ojetti V, Campanale MC, Tortora A, Cesario V, et al. 13C-Urea breath test for the diagnosis of Helicobacter pylori infection. Eur Rev Med Pharmacol Sci. 2013;17(Suppl 2):51–8.PubMed
21.
Naito Y, Yoshikawa T, Iinuma S, Yagi N, Matsuyama K, Boku Y, et al. Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study. Dig Dis Sci. 1998;43:83S–9S.PubMed
22.
Lanza FL, Royer GL Jr, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med. 1980;303:136–8.CrossRefPubMed
23.
Chitapanarux T, Praisontarangkul OA, Lertprasertsuke N. An open-labeled study of rebamipide treatment in chronic gastritis patients with dyspeptic symptoms refractory to proton pump inhibitors. Dig Dis Sci. 2008;53:2896–903.CrossRefPubMed
24.
Sakaki N, Kozawa H, Egawa N, Tu Y, Sanaka M. Ten-year prospective follow-up study on the relationship between Helicobacter pylori infection and progression of atrophic gastritis, particularly assessed by endoscopic findings. Aliment Pharmacol Ther. 2002;16(Suppl 2):198–203.CrossRefPubMed
25.
Asaka M, Sugiyama T, Nobuta A, Kato M, Takeda H, Graham DY. Atrophic gastritis and intestinal metaplasia in Japan: results of a large multicenter study. Helicobacter. 2001;6:294–9.CrossRefPubMed
26.
27.
Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2002;2:28–37.CrossRefPubMed
28.
29.
Cheung TK, Xia HH, Wong BC. Helicobacter pylori eradication for gastric cancer prevention. J Gastroenterol. 2007;42(Suppl 17):10–5.CrossRefPubMed
30.
Arakawa T, Higuchi K, Fujiwara Y, Watanabe T, Tominaga K, Sasaki E, et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50(Suppl 1):S3–11.CrossRefPubMed
31.
Tarnawski A, Arakawa T, Kobayashi K. Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci. 1998;43:90S–8S.CrossRefPubMed
32.
Nishizawa T, Suzuki H, Nakagawa I, Minegishi Y, Masaoka T, Iwasaki E, et al. Rebamipide-promoted restoration of gastric mucosal sonic hedgehog expression after early Helicobacter pylori eradication. Digestion. 2009;79:259–62.CrossRefPubMed
33.
Kinjo N, Kawanaka H, Akahoshi T, Yamaguchi S, Yoshida D, Anegawa G, et al. Significance of ERK nitration in portal hypertensive gastropathy and its therapeutic implications. Am J Physiol Gastrointest Liver Physiol. 2008;295:G1016–24.CrossRefPubMed
34.
Tarnawski AS, Chai J, Pai R, Chiou SK. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004;49:202–9.CrossRefPubMed
35.
Leung WK, Yu J, Chan FK, To KF, Chan MW, Ebert MP, et al. Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues. J Pathol. 2002;197:582–8.CrossRefPubMed
Metadata
Title
Effect of Rebamipide on the Premalignant Progression of Chronic Gastritis: A Randomized Controlled Study
Authors
Xue Han
Kui Jiang
Bangmao Wang
Lu Zhou
Xin Chen
Shu Li
Publication date
01-10-2015
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 10/2015
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.1007/s40261-015-0329-z

Other articles of this Issue 10/2015

Clinical Drug Investigation 10/2015 Go to the issue

Short Communication

Is Blood Eosinophil Count a Predictor of Response to Bronchodilators in Chronic Obstructive Pulmonary Disease? Results from Post Hoc Subgroup Analyses

Original Research Article

Pharmacokinetic and Pharmacodynamic Comparison of Two Recombinant Human Erythropoietin Formulations, PDA10 and Eprex, in Healthy Korean Male Volunteers: A Randomized, Double-Blinded, Single-Dose, Two-Period Crossover Study

Original Research Article

Assessment of Alcohol-Induced Dose Dumping with a Hydrocodone Bitartrate Extended-Release Tablet Formulated with CIMA® Abuse Deterrence Technology

Original Research Article

Association of Meloxicam Use with the Risk of Acute Pancreatitis: A Case–Control Study

Original Research Article

A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults

Original Research Article

Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol after Intravenous and Oral Administration